` SIGHT (Gensight Biologics SA) vs DAX Index Comparison - Alpha Spread

SIGHT
vs
D
DAX Index

Over the past 12 months, SIGHT has underperformed DAX Index, delivering a return of -74% compared to the DAX Index's +12% growth.

Stocks Performance
SIGHT vs DAX Index

Loading
SIGHT
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SIGHT vs DAX Index

Loading
SIGHT
DAX Index
Difference
www.alphaspread.com

Performance By Year
SIGHT vs DAX Index

Loading
SIGHT
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Gensight Biologics SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Gensight Biologics SA
Glance View

Market Cap
15.1m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.2129 EUR
Undervaluation 63%
Intrinsic Value
Price
Back to Top